These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14520118)

  • 1. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients.
    Yasui-Furukori N; Kondo T; Mihara K; Suzuki A; Inoue Y; Kaneko S
    J Clin Psychopharmacol; 2003 Oct; 23(5):435-40. PubMed ID: 14520118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics.
    Perry PJ; Miller DD; Arndt SV; Smith DA; Holman TL
    J Clin Psychopharmacol; 1993 Feb; 13(1):46-51. PubMed ID: 8486817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
    Ono S; Mihara K; Suzuki A; Kondo T; Yasui-Furukori N; Furukori H; de Vries R; Kaneko S
    Psychopharmacology (Berl); 2002 Jun; 162(1):50-4. PubMed ID: 12107617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood levels of haloperidol in schizophrenic patients.
    Shvartsburd A; Dekirmenjian H; Smith RC
    J Clin Psychopharmacol; 1983 Feb; 3(1):7-12. PubMed ID: 6833528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
    Chang WH; Lin SK; Jann MW
    J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia.
    Nakamura A; Mihara K; Nagai G; Suzuki T; Kondo T
    Ther Drug Monit; 2009 Oct; 31(5):575-8. PubMed ID: 19701114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic protocol for predicting plasma haloperidol concentrations.
    Miller DD; Perry PJ; Kelly MW; Coryell WH; Arndt SV
    J Clin Psychopharmacol; 1990 Jun; 10(3):207-12. PubMed ID: 2376619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
    Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroleptic radioreceptor activity and clinical outcome in schizophrenia.
    Contreras S; Alexander H; Faber R; Bowden C
    J Clin Psychopharmacol; 1987 Apr; 7(2):95-8. PubMed ID: 3584527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
    Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
    J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Carbamazepine: an efficient adjuvant treatment in schizophrenia].
    Martín Muñoz JC; Moriñigo Domínguez AV; Mateo Martín I; Guajardo-Fajardo Ibarra I; Noval Lamos D
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1992; 20(1):11-6. PubMed ID: 1502960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse effects of risperidone and haloperidol treatment in schizophrenia.
    Yen YC; Lung FW; Chong MY
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients.
    Ulrich S; Sandmann U; Genz A
    Pharmacopsychiatry; 2005 Jul; 38(4):171-7. PubMed ID: 16025420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amoxapine as an antipsychotic: comparative study versus haloperidol.
    Chaudhry IB; Husain N; Khan S; Badshah S; Deakin B; Kapur S
    J Clin Psychopharmacol; 2007 Dec; 27(6):575-81. PubMed ID: 18004123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome.
    Panagiotidis G; Arthur HW; Lindh JD; Dahl ML; Sjöqvist F
    Ther Drug Monit; 2007 Aug; 29(4):417-22. PubMed ID: 17667795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia.
    Yasui-Furukori N; Kondo T; Mihara K; Inoue Y; Kaneko S
    Psychopharmacology (Berl); 2004 Jan; 171(2):223-7. PubMed ID: 12955290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of carbamazepine on plasma haloperidol levels.
    Jann MW; Ereshefsky L; Saklad SR; Seidel DR; Davis CM; Burch NR; Bowden CL
    J Clin Psychopharmacol; 1985 Apr; 5(2):106-9. PubMed ID: 3988968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.